Prevalence, Phenotypes, and Comorbidities of Polycystic Ovary Syndrome Among Indian Women
Mohd Ashraf Ganie,Subhankar Chowdhury,Neena Malhotra,Rakesh Sahay,Prasanta Kumar Bhattacharya,Sarita Agrawal,P K Jabbar,Vanita Suri,Roya Rozati,Vishnubhatla Sreenivas,Mohammad Salem Baba,Imtiyaz Ahmad Wani,Haroon Rashid,Abhilash Nair,Amlin Shukla,Taruna Arora,Bharati Kulkarni,PCOS Study Group,Parvaiz Koul Dr,Zafar Amin Shah Dr,Shariq Masoodi Dr,Tabasuum Parvez Dr,Ghulam Nabi Yatoo Dr,Naseer Ahmad Chow Dr,Tariq Gojwari Dr,Muzaffar Wani Dr,Seema Qayoom Dr,Wahid Khan Dr,Rama Walia Dr,Deepenkar De Dr,Aashima Arora Dr,Tulika Singh Dr,Neena Khanna Dr,Nitish Naik Dr,Shyam Prakash Dr,Nandita Gupta Dr,Rajesh Sagar Dr,Jai Bhagwan Sharma Dr,Devasenathipathy Kandasamy Dr,Narender Kuber Bodhey Dr,Eli Mohapatra Dr,Sabah Siddiqui Dr,Gourisankar Kamilya Dr,Archana Singh Dr,Pradip Mukhopadhyay Dr,Nehar Ranjan Sarkar Dr,Alice Abraham Ruram Dr,Jessy Abraham Dr,Donboklang Lynser Dr,Manika Agrawal Dr,Laksman Rao Dr,Sudha Bindu Dr,Malathi Ponnuru Dr,Nadeem Ahmad Dr,Sujatha Rani Dr,Aleem Ahmad Khan Dr,Sultan Rizwan Ahmad Dr,Prabhakar Rao Dr,Nirmala C Dr,Anuja Elizabeth George Dr,Jayasree Leelamma Dr,Gaurav Thakur Dr,Saba Noor Dr,Khursheed Paddar Dr,Gaivee Vinam Meshram Dr,Shouvik Choudhary Dr,Aafia Rashid Dr,Wasia Showkat Dr,Rohina Bashir Dr,Rabiya Rashid Dr,Jabish Manzoor,Nisar Ahmad,Pieu Adhikary,Subhasish Pramanik,Rahul Harish Dr,Mudasir Makhdoomi Dr,Mudasir Fayaz,Nafeez Rehman,Neha Ravi,Ajay Kumar,Siffali Chandrakar,Nithlesh Kumar,Sudipta Banerjee,Humaira Minhaj Dr,Balaji Bhaskar Dr,Shaik Iqbal,Ram Babu,Arya Suresh,R S Sharma Dr,Shalini Singh Dr,Malabika Roy Dr,Reeta Rasilly Dr,Nomita Chandiok Dr,Mehnaaz Rajab Dr,Arifa Reshi Dr,Deeba Farhat Dr,Abid Rashid,Nusrat Jahan,Shavini Choudhary,Naila Mohiudin Dr,Samala Ranjith,Khalid Ul Islam Rather Dr
DOI: https://doi.org/10.1001/jamanetworkopen.2024.40583
2024-10-01
Abstract:Importance: The prevalence of polycystic ovary syndrome (PCOS) varies across the globe. Indian studies on PCOS are limited by poor design, small sizes, regional representations, and varying methods. Objectives: To estimate the nationwide prevalence of PCOS in India, examine the phenotypic spectrum, and assess the magnitude of comorbidities associated with PCOS. Design, setting, and participants: This cross-sectional study recruited 9824 women aged 18 to 40 years from November 1, 2018, to July 31, 2022, across 5 zones of the country. A prevalidated questionnaire dichotomized women into screen-positive and screen-negative groups. Relevant clinical, hormonal, and sonographic assessments categorized women as either women with criteria-based PCOS (ie, National Institutes of Health [NIH] 1990 criteria, Rotterdam 2003 criteria, or Androgen Excess and Polycystic Ovary Syndrome Society [AE-PCOS] criteria), women with partial phenotypes (hyperandrogenism, oligomenorrhea, or polycystic morphology labeled as pre-PCOS), or healthy women, in addition to quantitating various comorbidities. Main outcomes and measures: The prevalence and phenotypes of PCOS among women of reproductive age and the burden of comorbidities associated with PCOS. Results: A total of 8993 women (mean [SD] age, 29.5 [6.2] years) were enrolled in this study; 196 women were already diagnosed with PCOS, 2251 were categorized as screen positive, and 6546 were categorized as screen negative. The mean (SD) age of screen-positive women (28.1 [6.4] years) was lower than that of screen-negative women (29.7 [6.1] years) (P < .001), and the mean (SD) age at menarche was higher in the former group (13.2 [1.3] vs 13.1 [1.2] years; P < .001). The national prevalence of PCOS was 7.2% (95% CI, 4.8%-10.8%) by NIH 1990 criteria, 19.6% (95% CI, 12.7%-29.2%) by Rotterdam 2003 criteria, and 13.6% (95% CI, 8.4%-21.6%) by AE-PCOS criteria. Overall, PCOS phenotypes C (501 [40.8%]) and D (301 [24.6%]) were the most common, and 492 women (pre-PCOS subgroup) had oligomenorrhea (n = 75), hyperandrogenism (n = 257), or polycystic ovarian morphology (n = 160) only. Among women with PCOS (n = 1224), obesity was present in 529 (43.2%), dyslipidemia in 1126 (91.9%), nonalcoholic fatty liver disease in 403 (32.9%), metabolic syndrome in 305 (24.9%), impaired glucose tolerance in 111 (9.1%), diabetes in 41 (3.3%), and hypertension in 101 (8.3%). The pre-PCOS subgroup (n = 492) displayed similar metabolic aberrations (dyslipidemia: 390 [79.3%]; metabolic syndrome: 78 [15.9%]; nonalcoholic fatty liver disease: 163 [33.1%]; impaired glucose tolerance: 62 [12.6%]; diabetes: 7 [1.4%]; and hypertension: 26 [5.3%]). Conclusions and relevance: In this cross-sectional study of reproductive-age women recruited across India, the prevalence of PCOS was high, with phenotype C being predominant. Most of these women had metabolic abnormalities. These findings are crucial for developing preventive and therapeutic strategies, potentially integrating PCOS management into national health programs.